Alternative anti-angiogenetic strategies are already under investigation; recently, Rao and collaborators described a new drug, MP0250, that is able to bind and neutralize both VEGF and HGF, thus making an anti-angiogenic effect on MM in vivo [32]. This evidence concerns the gene HGF and Miyoshi myopathy.